Literature DB >> 16462611

Advances in prevention of cervical cancer and other human papillomavirus-related diseases.

Ian H Frazer1, J Thomas Cox, Edward John Mayeaux, Eduardo L Franco, Anna-Barbara Moscicki, Joel M Palefsky, Daron G Ferris, Alex S Ferenczy, Luisa L Villa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16462611     DOI： 10.1097/01.inf.0000196485.86376.46

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  9 in total

1.  The human papillomavirus vaccine: The promise of cervical cancer prevention.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

2.  Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.

Authors:  Francesco Saverio Mennini; Gianluca Fabiano; Andrea Marcellusi; Paolo Sciattella; Mario Saia; Silvia Cocchio; Vincenzo Baldo
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

3.  Prevalence of HPV infection and genotype distribution in women from Africa seeking asylum in Puglia, Italy.

Authors:  M Chironna; S Tafuri; A L De Robertis; A Sallustio; A Morea; A Napoli; D Martinelli; R Prato; C Germinario
Journal:  J Immigr Minor Health       Date:  2013-02

4.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

Review 5.  Indications and efficacy of the human papillomavirus vaccine.

Authors:  Amy A Hakim; Paul S Lin; Sharon Wilczynski; Kimhuynh Nguyen; Billie Lynes; Mark T Wakabayashi
Journal:  Curr Treat Options Oncol       Date:  2007-12

Review 6.  Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

Authors:  Susan J Keam; Diane M Harper
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Intake of food groups and cervical cancer in women at risk for cervical cancer: A nested case-control study.

Authors:  Mogge Hajiesmaeil; Samaneh Mirzaei Dahka; Ruin Khorrami; Samira Rastgoo; Fatemeh Bourbour; Sayed Hossein Davoodi; Fatemeh Shafiee; Maryam Gholamalizadeh; Saheb Abbas Torki; Mohammad Esmail Akbari; Saeid Doaei
Journal:  Caspian J Intern Med       Date:  2022

Review 8.  Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.

Authors:  Simona Di Mario; Vittorio Basevi; Pier Luigi Lopalco; Sara Balduzzi; Roberto D'Amico; Nicola Magrini
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

9.  Behavioral Perceptions of Oakland University Female College Students towards Human Papillomavirus Vaccination.

Authors:  Aishwarya Navalpakam; Mohammed Dany; Inaya Hajj Hussein
Journal:  PLoS One       Date:  2016-05-20       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.